Trypanosoma cruzi CYP51 inhibitor derived from a Mycobacterium tuberculosis screen hit

PLoS Neglected Tropical Diseases

Volumn 3, Issue 2, 2009, Pages

  Chen, Chiung Kuang ^a   Doyle, Patricia S ^a   Yermalitskaya, Liudmila V ^b   Mackey, Zachary B ^a   Ang, Kenny K H ^a   McKerrow, James H ^a   Podust, Larissa M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 [[(4 METHYLPHENYL)SULFONYL]AMINO]PROPYLPYRIDIN 4 YLCARBAMATE; ANTIPARASITIC AGENT; CIS 4 METHYL N[3 (METHYLSULFANYL) 1 (PYRIDIN 4 YLCARBAMOYL)PROPYL]CYCLOHEXANECARBOXAMIDE; FLUCONAZOLE; ISOLEUCINE; N [2 METHYL 1(PYRIDIN 4 YLCARBAMOYL)PROPYL]CYCLOHEXANECARBOXAMIDE; N [4 PYRIDYL]FORMAMIDE DERIVATIVE; PHENYLALANINE; STEROL 14ALPHA DEMETHYLASE; STEROL 14ALPHA DEMETHYLASE INHIBITOR; UNCLASSIFIED DRUG; ANTITRYPANOSOMAL AGENT; CYP51 PROTEIN, TRYPANOSOMA CRUZI; CYTOCHROME P450; ENZYME INHIBITOR;

AFRICAN TRYPANOSOMIASIS; ANIMAL CELL; ARTICLE; BINDING SITE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; ENZYME INHIBITION; ENZYME STRUCTURE; HUMAN; HUMAN CELL; MACROPHAGE; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; STRUCTURE ANALYSIS; TRYPANOSOMA BRUCEI; TRYPANOSOMA CRUZI; ANIMAL; CATTLE; CELL CULTURE; CELL SURVIVAL; CHAGAS DISEASE; DRUG ANTAGONISM; DRUG EFFECT; DRUG SENSITIVITY; ENZYMOLOGY; IC 50; PARASITOLOGY;

ANIMALS; CATTLE; CELL SURVIVAL; CELLS, CULTURED; CHAGAS DISEASE; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; HUMANS; INHIBITORY CONCENTRATION 50; MICE; MYCOBACTERIUM TUBERCULOSIS; PARASITIC SENSITIVITY TESTS; TRYPANOCIDAL AGENTS; TRYPANOSOMA CRUZI;

EID: 65549090030     PISSN: None     EISSN: None     Source Type: Journal    
DOI: 10.1371/journal.pntd.0000372     Document Type: Article

References (36)

1. Nwaka S, Hudson A (2006) Innovative lead discovery strategies for tropical diseases. Nat Rev Drug Discov 5: 941-955.
2. Schofield CJ, Jannin J, Salvatella R (2006) The future of Chagas disease control. Trends Parasitol 22: 583-588.
3. Chagas C (1909) Nova trypanosomiase humana. Gaceta Medica da Bahia 40: 433-440.
4. Organization WH (2002) Control of Chagas disease: second report of the WHO expert committee. Geneva: WHO.
5. Docampo R, Schmunis GA (1997) Sterol biosynthesis inhibitors: potential chemotherapeutics against Chagas disease. Parasitol Today 13: 129-130.
6. Aoyama Y (2005) Recent progress in the CYP51 research focusing on its unique evolutionary and functional characteristics as a diversozyme P450. Front Biosci 10: 1546-1557.
7. Furlong ST (1989) Sterols of parasitic protozoa and helminths. Exp Parasitol 68: 482-485.
8. Georgopapadakou NH (1998) Antifungals: mechanism of action and resistance, established and novel drugs. Curr Opin Microbiol 1: 547-557.
9. Sheehan DJ, Hitchcoch CA, Sibley CM (1999) Current and emerging azole antifungal agents. Clin Microbiol Rev 12: 40-79.
10. Mishra J, Saxena A, Singh S (2007) Chemotherapy of leishmaniasis: past, present and future. Curr Med Chem 14: 1153-1169.
11. Roberts CW, McLeod R, Rice DW, Ginger M, Chance ML, et al. (2003) Fatty acid and sterol metabolism: potential antimicrobial targets in apicomplexan and trypanosomatid parasitic protozoa. Mol Biochem Parasitol 126: 129-142.
12. Maya JD, Cassels BK, Iturriaga-Vasquez P, Ferreira J, Faundez M, et al. (2007) Mode of action of natural and synthetic drugs against Trypanosoma cruzi and their interaction with the mammalian host. Comp Biochem Physiol A Mol Integr Physiol 146: 601-620.
13. Urbina JA, Payares G, Molina J, Sanoja C, Liendo A, et al. (1996) Cure of short- and long-term experimental Chagas' disease using D0870. Science 273: 969-971.
14. Buckner F, Yokoyama K, Lockman J, Aikenhead K, Ohkanda J, et al. (2003) A class of sterol 14-demethylase inhibitors as anti-Trypanosoma cruzi agents. Proc Natl Acad Sci U S A 100: 15149-15153.
15. Urbina JA, Payares G, Sanoja C, Molina J, Lira R, et al. (2003) Parasitological cure of acute and chronic experimental Chagas disease using the long-acting experimental triazole TAK-187. Activity against drug-resistant Trypanosoma cruzi strains. Int J Antimicrob Agents 21: 39-48.
16. Podust LM, Poulos TL, Waterman MR (2001) Crystal structure of cytochrome P450 14α-sterol demethylase (CYP51) from Mycobacterium tuberculosis in complex with azole inhibitors. Proc Natl Acad Sci USA 98: 3068-3073.
17. Podust LM, Stojan J, Poulos TL, Waterman MR (2001) Substrate recognition sites in 14α-sterol demethylase from comparative analysis of amino acid sequences and X-ray structure of Mycobacterium tuberculosis CYP51. J Inorg Biochem 87: 227-235.
18. Podust LM, Yermalitskaya LV, Lepesheva GI, Podust VN, Dalmasso EA, et al. (2004) Estriol bound and ligand-free structures of sterol 14α-demethylase. Structure 12: 1937-1945.
19. Podust LM, von Kries JP, Nasser Eddine A, Kim Y, Yermalitskaya LV, et al. (2007) Small molecule scaffolds for CYP51 inhibitors identified by high-throughput screening and defined by x-ray crystallography. Antimicrob Agents Chemother 51: 3915-3923.
20. Nasser Eddine A, von Kries JP, Podust MV, Warrier T, Kaufmann SH, et al. (2008) X-ray structure of 4,4′-dihydroxybenzophenone mimicking sterol substrate in the active site of sterol 14alpha-demethylase (CYP51). J Biol Chem 283: 15152-15159.
21. Lepesheva GI, Zaitseva NG, Nes WD, Zhou W, Arase M, et al. (2006) CYP51 from Trypanosoma cruzi: a phyla-specific residue in the B′ helix defines substrate preferences of sterol 14α-demethylase. J Biol Chem 281: 3577-3585.
22. Buckner FS, Joubert BM, Boyle SM, Eastman RT, Verlinde CL, et al. (2003) Cloning and analysis of Trypanosoma cruzi lanosterol 14alpha-demethylase. Mol Biochem Parasitol 132: 75-81.
23. von Wachenfeldt C, Richardson TH, Cosme J, Johnson EF (1997) Microsomal P450 2C3 is expressed as a soluble dimer in Escherichia coli following modification of its N-terminus. Arch Biochem Biophys 339: 107-114.
24. Barnes HJ, Arlotto MP, Waterman MR (1991) Expression and enzymatic activity of recombinant cytochrome P450 17 alpha-hydroxylase in Escherichia coli. Proc Natl Acad Sci U S A 88: 5597-5601.
25. Otwinowski Z, Minor W (1997) Processing of x-ray diffraction data collected in oscillation mode. Methods Enzymol 276: 307-326.
26. Murshudov GN, Vagin AA, Dodson EJ (1997) Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D Biol Crystallogr 53: 240-255.
27. Emsley P, Cowtan K (2004) Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 60: 2126-2132.
28. Laskowski RA, MacArthur MW, Moss DS, Thornton JM (1993) PROCHECK: a program to check the stereochemical quality of protein structures. J Appl Crystallogr 26: 283-291.
29. Omura T, Sato R (1964) The carbon monoxide-binding pigment of liver microsomes. II. Solubilization, purification, and properties. J Biol Chem 239: 2379-2385.
30. Engel JC, Doyle PS, Hsieh I, McKerrow JH (1998) Cysteine protease inhibitors cure an experimental Trypanosoma cruzi infection. J Exp Med 188: 725-734.
31. Doyle PS, Zhou YM, Engel JC, McKerrow JH (2007) A cysteine protease inhibitor cures Chagas' disease in an immunodeficient-mouse model of infection. Antimicrob Agents Chemother 51: 3932-3939.
32. Doyle PS, Dvorak JA, Engel JC (1984) Trypanosoma cruzi: quantification and analysis of the infectivity of cloned stocks. J Protozool 31: 280-283.
33. Lepesheva GI, Nes WD, Zhou W, Hill GC, Waterman MR (2004) CYP51 from Trypanosoma brucei is obtusifoliol-specific. Biochemistry 43: 10789-10799.
34. Bird CW, Lynch JM, Pirt FJ, Reid WW (1971) Steroids and squalene in Methylococcus capsulatus grown on methane. Nature 230: 473-474.
35. Humphrey W, Dalke A, Schulten K (1996) VMD: visual molecular dynamics. J Mol Graph 14: 33-38.
36. DeLano WL (2002) The PyMOL molecular graphics system. San Carlos, CA, USA: DeLano Scientific.